Abstract
Background: In many fields of medicine, guidelines recommend reduced cancer screening in patients of advanced age with limited life expectancy (LLE). In dermatology, there are currently no guidelines for adjusted evaluation and management practices of keratinocyte cancer (KC) in patients with LLE. Little is known regarding evaluation and management patterns and frequency of biopsies in these patients. Objective: We sought to determine if dermatology providers biopsy LLE patients with similar frequency to their age-matched peers and quantify frequency of associated complications. Methods: This was a retrospective cohort study of evaluations for skin cancer quantified by skin biopsy frequency at the North Texas Veterans Affairs Health System dermatology clinic for 3,062 patients between 2005 and 2009, including a 5-year follow-up period. Life expectancy was quantified by the validated Charlson Comorbidity Index (CCI) with a Deyo adaptation. Results: There was no significant difference in biopsy frequency of KC in LLE versus non-LLE patients in most age-controlled groups, with increased biopsy frequency in LLE patients in the 65–74 age category (p = 0.02). There was also an increased risk of complications from biopsy in the 75–84 (many comorbidities subgroup: RR = 3.27, p = 0.002; some comorbidities subgroup: RR = 2.26, p = 0.048) and 65–74 (many comorbidities subgroup: RR = 1.52, p = 0.004) age groups when compared to age-matched healthy controls. Conclusion: Biopsy frequency is similar or increased in patients with LLE compared with age-matched controls, with increased frequency of complications. Further studies are needed to understand the underlying factors driving these practice patterns.
Journal Section:
Skin Cancer – Research Article
References
1.
Cameron
MC
, Lee
E
, Hibler
BP
, Barker
CA
, Mori
S
, Cordova
M
. Basal cell carcinoma: epidemiology; pathophysiology; clinical and histological subtypes; and disease associations
. J Am Acad Dermatol
. 2019
;80
(2
):303
–17
.2.
Asgari
MM
, Moffet
HH
, Ray
GT
, Quesenberry
CP
. Trends in basal cell carcinoma incidence and identification of high-risk subgroups, 1998-2012
. JAMA Dermatol
. 2015
;151
(9
):976
–81
.3.
Leiter
U
, Keim
U
, Eigentler
T
, Katalinic
A
, Holleczek
B
, Martus
P
. Incidence, mortality, and trends of nonmelanoma skin cancer in Germany
. J Invest Dermatol
. 2017
;137
(9
):1860
–7
.4.
Eisemann
N
, Waldmann
A
, Geller
AC
, Weinstock
MA
, Volkmer
B
, Greinert
R
. Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence
. J Invest Dermatol
. 2014
;134
(1
):43
–50
.5.
Eigentler
TK
, Leiter
U
, Häfner
HM
, Garbe
C
, Röcken
M
, Breuninger
H
. Survival of patients with cutaneous squamous cell carcinoma: results of a prospective cohort study
. J Invest Dermatol
. 2017
;137
(11
):2309
–15
.6.
Schmults
CD
, Karia
PS
, Carter
JB
, Han
J
, Qureshi
AA
. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study
. JAMA Dermatol
. 2013
;149
(5
):541
–7
.7.
Work Group
Invited Reviewers
Kim
JYS
, Kozlow
JH
, Mittal
B
, Moyer
J
. Guidelines of care for the management of basal cell carcinoma
. J Am Acad Dermatol
. 2018
;78
(3
):540
–59
.8.
Work Group
Invited Reviewers
Kim
JYS
, Kozlow
JH
, Mittal
B
, Moyer
J
. Guidelines of care for the management of cutaneous squamous cell carcinoma
. J Am Acad Dermatol
. 2018
;78
(3
):560
–78
.9.
Garcovich
S
, Colloca
G
, Sollena
P
, Andrea
B
, Balducci
L
, Cho
WC
. Skin cancer epidemics in the elderly as an emerging issue in geriatric Oncology
. Aging Dis
. 2017
;8
(5
):643
–61
.10.
Bailey
A
, Vasicek
B
, Tao
J
, Janeczek
M
, Mitri
A
, Tung
R
. Management of keratinocyte carcinoma: special considerations in the elderly
. Int J Womens Dermatol
. 2019
;5
(4
):235
–45
.11.
Linos
E
, Berger
T
, Chren
MM
. Point: care of potential low-risk basal cell carcinomas (BCCs) at the end of life: the key role of the dermatologist
. J Am Acad Dermatol
. 2015
;73
(1
):158
–61
.12.
Lubeek
SFK
, Borgonjen
RJ
, van Vugt
LJ
, Olde Rikkert
MG
, van de Kerkhof
PCM
, Gerritsen
MJP
. Improving the applicability of guidelines on nonmelanoma skin cancer in frail older adults: a multidisciplinary expert consensus and systematic review of current guidelines
. Br J Dermatol
. 2016
;175
(5
):1003
–10
.13.
Linos
E
, Parvataneni
R
, Stuart
SE
, Boscardin
WJ
, Landefeld
CS
, Chren
MM
. Treatment of nonfatal conditions at the end of life: nonmelanoma skin cancer
. JAMA Intern Med
. 2013
;173
(11
):1006
–12
.14.
Rieger
KE
, Linos
E
, Egbert
BM
, Swetter
SM
. Recurrence rates associated with incompletely excised low-risk nonmelanoma skin cancer
. J Cutan Pathol
. 2010
;37
(1
):59
–67
.15.
Deyo
RA
, Cherkin
DC
, Ciol
MA
. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
. J Clin Epidemiol
. 1992
;45
(6
):613
–9
.16.
Mortensen
EM
, Coley
CM
, Singer
DE
, Marrie
TJ
, Obrosky
DS
, Kapoor
WN
. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study
. Arch Intern Med
. 2002
;162
(9
):1059
–64
.17.
Çıldır
E
, Bulut
M
, Akalın
H
, Kocabaş
E
, Ocakoğlu
G
, Aydın
ŞA
. Evaluation of the modified MEDS, MEWS score and Charlson comorbidity index in patients with community acquired sepsis in the emergency department
. Intern Emerg Med
. 2013
;8
(3
):255
–60
.18.
Thyssen
JP
, Skov
L
, Hamann
CR
, Gislason
GH
, Egeberg
A
. Assessment of major comorbidities in adults with atopic dermatitis using the Charlson comorbidity index
. J Am Acad Dermatol
. 2017
;76
(6
):1088
92.e1
.19.
Blair
MJ
, Jones
JD
, Woessner
AE
, Quinn
KP
. Skin structure-function relationships and the wound healing response to intrinsic aging
. Adv Wound Care
. 2020
;9
(3
):127
–43
.20.
Linos
E
, Chren
MM
, Stijacic Cenzer
I
, Covinsky
KE
. Skin cancer in U.S. Elderly adults: does life expectancy play a role in treatment decisions
. J Am Geriatr Soc
. 2016
;64
(8
):1610
–5
.21.
Royce
TJ
, Hendrix
LH
, Stokes
WA
, Allen
IM
, Chen
RC
. Cancer screening rates in individuals with different life expectancies
. JAMA Intern Med
. 2014
;174
(10
):1558
–65
.22.
Carter
HB
, Albertsen
PC
, Barry
MJ
, Etzioni
R
, Freedland
SJ
, Greene
KL
. Early detection of prostate cancer: AUA Guideline
. J Urol
. 2013
;190
(2
):419
–26
.23.
Qaseem
A
, Crandall
CJ
, Mustafa
RA
, Hicks
LA
, Wilt
TJ
Clinical Guidelines Committee of the American College of Physicians
. Screening for colorectal cancer in asymptomatic average-risk adults: a guidance statement from the American college of physicians
. Ann Intern Med
. 2019
;171
(9
):643
–54
.24.
US Preventive Services Task Force
Curry
SJ
, Krist
AH
, Owens
DK
, Barry
MJ
, Caughey
AB
. Screening for cervical cancer: US preventive services task force recommendation statement
. JAMA
. 2018
;320
(7
):674
–86
.25.
Siu
AL
U.S. Preventive Services Task Force
. Screening for breast cancer: U.S. Preventive services task force recommendation statement
. Ann Intern Med
. 2016
;164
(4
):279
–96
.26.
Stewart
CMM
, Garlick
J
, McMullin
J
, Siddiqi
F
, Crombie
C
, Rockwell
WB
. Surgical excision of non-melanoma skin cancer in an elderly veteran’s Affairs population
. Plast Reconstr Surg Glob Open
. 2014
;2
(12
):e277
.27.
Bichakjian
CK
, Olencki
T
, Aasi
SZ
, Alam
M
, Andersen
JS
, Berg
D
. Basal cell skin cancer, version 1.2016, NCCN clinical practice guidelines in Oncology
. J Natl Compr Canc Netw
. 2016
;14
(5
):574
–97
.28.
Schmults
CD
, Blitzblau
R
, Aasi
SZ
, Alam
M
, Andersen
JS
, Baumann
BC
. NCCN Guidelines® insights: squamous cell skin cancer, version 1.2022
. J Natl Compr Canc Netw
. 2021
;19
(12
):1382
–94
.© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
